{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:12:22Z","timestamp":1793124742442,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.critrevonc.2026.105353","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:39:24Z","timestamp":1777617564000},"page":"105353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Overcoming conditional immune resistance in MSS and pMMR colorectal cancer: A sequential gating framework for immunotherapy"],"prefix":"10.1016","volume":"223","author":[{"given":"Husni","family":"Farah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djamila","family":"Polatova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasur","family":"Rizaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faez Ahmed","family":"Mhdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faris Anad","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laxmidhar","family":"Maharana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Bainsal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritesh","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2026.105353_bib1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1186\/s12885-020-07169-6","article-title":"AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer","volume":"20","author":"Antoniotti","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105353_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.903564","article-title":"Colorectal cancer-infiltrating regulatory T cells: functional heterogeneity, metabolic adaptation, and therapeutic targeting","volume":"13","author":"Aristin Revilla","year":"2022","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105353_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005923","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies","volume":"11","author":"Atkins","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105353_bib4","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.3389\/fonc.2020.01290","article-title":"Mechanisms of Cancer Resistance to Immunotherapy","volume":"10","author":"Bai","year":"2020","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105353_bib5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13148-023-01485-x","article-title":"A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer","volume":"15","author":"Baretti","year":"2023","journal-title":"Clin. Epigenetics"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105353_bib6","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.cell.2019.02.005","article-title":"Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4(+) T Cell Immunity","volume":"177","author":"Binnewies","year":"2019","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105353_bib7","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105353_bib8","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.7150\/ijbs.93697","article-title":"Using Combination therapy to overcome diverse challenges of Immune Checkpoint Inhibitors treatment","volume":"20","author":"Birnboim-Perach","year":"2024","journal-title":"Int J. Biol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105353_bib9","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold Tumors: A Therapeutic Challenge for Immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105353_bib10","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41591-024-03083-7","article-title":"Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial","volume":"30","author":"Bullock","year":"2024","journal-title":"Nat. Med"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105353_bib11","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/imm.13785","article-title":"A new strategy for immunotherapy of microsatellite-stable (MSS)-type advanced colorectal cancer: multi-pathway combination therapy with PD-1\/PD-L1 inhibitors","volume":"173","author":"Cai","year":"2024","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105353_bib12","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1038\/s41467-018-06654-8","article-title":"TGF-beta-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure","volume":"9","author":"Chakravarthy","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105353_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"7637","key":"10.1016\/j.critrevonc.2026.105353_bib14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105353_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104775","article-title":"Immunotherapy in microsatellite-stable colorectal cancer: Strategies to overcome resistance","volume":"212","author":"Chen","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105353_bib16","article-title":"Efficacy of immune checkpoint inhibitors combined with bevacizumab in MSS\/pMMR advanced colorectal cancer after first-line treatment failure","volume":"14","author":"Chen","year":"2024","journal-title":"Front Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105353_bib17","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1001\/jamaoncol.2018.4942","article-title":"Association of primary resistance to immune checkpoint inhibitors in metastatic colorectal cancer with misdiagnosis of microsatellite instability or mismatch repair deficiency status","volume":"5","author":"Cohen","year":"2019","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105353_bib18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13148-024-01740-9","article-title":"Epigenetics and immunotherapy in colorectal cancer: progress and promise","volume":"16","author":"Dang","year":"2024","journal-title":"Clin. Epigenetics"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105353_bib19","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41577-021-00541-y","article-title":"Metabolic barriers to cancer immunotherapy","volume":"21","author":"DePeaux","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105353_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.552331","article-title":"Computational tumor infiltration phenotypes enable the spatial and genomic analysis of immune infiltration in colorectal cancer","volume":"11","author":"Failmezger","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105353_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101917","article-title":"Regorafenib plus nivolumab in patients with mismatch repair-proficient\/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study","volume":"58","author":"Fakih","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"39","key":"10.1016\/j.critrevonc.2026.105353_bib22","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1200\/EDBK_240837","article-title":"Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients?","author":"Fares","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book 39"},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105353_bib23","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib Trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105353_bib24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.immuni.2019.12.018","article-title":"Tumor immunology and tumor evolution: intertwined histories","volume":"52","author":"Galon","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2026.105353_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1161048","article-title":"The role of immunotherapy in microsatellites stable metastatic colorectal cancer: state of the art and future perspectives","volume":"13","author":"Gandini","year":"2023","journal-title":"Front Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105353_bib26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41575-021-00569-4","article-title":"Optimizing immunotherapy for colorectal cancer","volume":"19","author":"Ganesh","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105353_bib27","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105353_bib28","article-title":"Real world effectiveness of chemotherapy plus bevacizumab with immunotherapy in colorectal cancer","volume":"15","author":"Gao","year":"2025","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105353_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14010052","article-title":"Immune Checkpoint Inhibitors in Mismatch Repair Proficient\/Microsatellite Stable Metastatic Colorectal Cancer Patients: Insights from the AtezoTRIBE and MAYA Trials","volume":"14","author":"Germani","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105353_bib30","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat. Med"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105353_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011040","article-title":"Immune-related adverse events of neoadjuvant immunotherapy in patients with perioperative cancer: a machine-learning-driven, decade-long informatics investigation","volume":"13","author":"Guo","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105353_bib32","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1093\/oncolo\/oyae013","article-title":"The efficacy of immune checkpoint inhibitors in microsatellite stable colorectal cancer: a systematic review","volume":"29","author":"Guven","year":"2024","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105353_bib33","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s11912-024-01583-w","article-title":"Immunotherapy for Microsatellite-Stable Metastatic Colorectal Cancer: Can we close the Gap between Potential and Practice?","volume":"26","author":"Hamid","year":"2024","journal-title":"Curr. Oncol. Rep."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105353_bib34","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1038\/s41588-025-02380-2","article-title":"TGF-beta builds a dual immune barrier in colorectal cancer by impairing T cell recruitment and instructing immunosuppressive SPP1(+) macrophages","volume":"57","author":"Henriques","year":"2025","journal-title":"Nat. Genet"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105353_bib35","article-title":"Impact of the tumor immune contexture in microsatellite-stable metastatic colorectal cancer treated with avelumab, cetuximab, and irinotecan","volume":"6","author":"Huyghe","year":"2025","journal-title":"Cell Rep. Med"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105353_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14092241","article-title":"Biomarkers of response and resistance to immunotherapy in microsatellite stable colorectal cancer: toward a new personalized medicine","volume":"14","author":"Huyghe","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105353_bib37","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","article-title":"A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade","volume":"175","author":"Jerby-Arnon","year":"2018","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105353_bib38","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1007\/s00262-022-03200-w","article-title":"Role of the cGAS-STING pathway in regulating the tumor-immune microenvironment in dMMR\/MSI colorectal cancer","volume":"71","author":"Kaneta","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105353_bib39","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.21873\/anticanres.15080","article-title":"Molecular and Radiological Features of Microsatellite Stable Colorectal Cancer Cases With Dramatic Responses to Immunotherapy","volume":"41","author":"Keenan","year":"2021","journal-title":"Anticancer Res"},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105353_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194906","article-title":"Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer","volume":"13","author":"Kim","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105353_bib41","article-title":"Identification of beneficial populations for targeted-immunotherapy combinations: tailoring later-line care for patients with pMMR\/MSS metastatic colorectal cancer","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105353_bib42","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s13046-025-03544-y","article-title":"The cGAS-STING pathway in colorectal cancer: bridging innate immunity and therapeutic strategies","volume":"44","author":"Li","year":"2025","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"7693","key":"10.1016\/j.critrevonc.2026.105353_bib43","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105353_bib44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.33696\/cancerimmunol.7.100","article-title":"Immunotherapy in MSS\/pMMR Metastatic Colorectal Cancer\u2013Insights from the KEYNOTE-651","volume":"7","author":"Miao","year":"2024","journal-title":"J. Cancer Immunol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105353_bib45","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41422-020-0337-2","article-title":"The future of cancer immunotherapy: microenvironment-targeting combinations","volume":"30","author":"Murciano-Goroff","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.critrevonc.2026.105353_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1353787","article-title":"Involvement of tumor immune microenvironment metabolic reprogramming in colorectal cancer progression, immune escape, and response to immunotherapy","volume":"15","author":"Nicolini","year":"2024","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105353_bib47","doi-asserted-by":"crossref","first-page":"495","DOI":"10.37349\/etat.2024.00231","article-title":"Resistance to immune checkpoint inhibitors in colorectal cancer with deficient mismatch repair\/microsatellite instability: misdiagnosis, pseudoprogression and\/or tumor heterogeneity?","volume":"5","author":"Normanno","year":"2024","journal-title":"Explor Target Antitumor Ther."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105353_bib48","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O'Donnell","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105353_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1571731","article-title":"Comprehensive review of the resistance mechanisms of colorectal cancer classified by therapy type","volume":"16","author":"Oh","year":"2025","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2026.105353_bib50","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.3389\/fimmu.2019.02453","article-title":"T Regulatory Cells and Priming the Suppressive Tumor Microenvironment","volume":"10","author":"Paluskievicz","year":"2019","journal-title":"Front Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105353_bib51","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105353_bib52","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.1016\/j.cell.2021.08.003","article-title":"Spatially organized multicellular immune hubs in human colorectal cancer","volume":"184","author":"Pelka","year":"2021","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105353_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17111854","article-title":"Oncolytic viruses as a novel therapeutic approach for colorectal cancer: mechanisms, current advances, and future directions","volume":"17","author":"Perez-Dominguez","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105353_bib54","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2147\/OTT.S500281","article-title":"Progress of Immune Checkpoint Inhibitors Therapy for pMMR\/MSS Metastatic Colorectal Cancer","volume":"17","author":"Qu","year":"2024","journal-title":"Onco Targets Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105353_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20040959","article-title":"Realizing the clinical potential of immunogenic cell death in cancer chemotherapy and radiotherapy","volume":"20","author":"Rapoport","year":"2019","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105353_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.961796","article-title":"Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option","volume":"13","author":"Ren","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2026.105353_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1112276","article-title":"Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer","volume":"13","author":"Ros","year":"2023","journal-title":"Front Oncol."},{"issue":"42","key":"10.1016\/j.critrevonc.2026.105353_bib58","first-page":"1","article-title":"Immunotherapy for microsatellite stable colorectal cancers: challenges and novel therapeutic avenues","author":"Sahin","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book 42"},{"key":"10.1016\/j.critrevonc.2026.105353_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.702726","article-title":"Regulatory T cells: barriers of immune infiltration into the tumor microenvironment","volume":"12","author":"Scott","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105353_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1016646","article-title":"Mechanism and strategies of immunotherapy resistance in colorectal cancer","volume":"13","author":"Shan","year":"2022","journal-title":"Front Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105353_bib61","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-Residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105353_bib62","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008210","article-title":"Multiomic molecular characterization of the response to combination immunotherapy in MSS\/pMMR metastatic colorectal cancer","volume":"12","author":"Takei","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"7693","key":"10.1016\/j.critrevonc.2026.105353_bib63","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105353_bib64","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1038\/s41416-023-02392-x","article-title":"Advancing translational research for colorectal immuno-oncology","volume":"129","author":"Thomas","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105353_bib65","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.adro.2018.08.018","article-title":"Role of the immunosuppressive microenvironment in immunotherapy","volume":"3","author":"Tormoen","year":"2018","journal-title":"Adv. Radiat. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105353_bib66","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013110","article-title":"Categorizing immunotherapy resistance mechanisms in non-small cell lung cancer: how can we perform better?","volume":"13","author":"van der Geest","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105353_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040935","article-title":"Future Challenges in Cancer Resistance to Immunotherapy","volume":"12","author":"van Elsas","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105353_bib68","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ccell.2018.03.008","article-title":"The immune revolution: a case for priming, not checkpoint","volume":"33","author":"Vonderheide","year":"2018","journal-title":"Cancer Cell"},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105353_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810906","article-title":"Cancer resistance to immunotherapy: molecular mechanisms and tackling strategies","volume":"23","author":"Vu","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105353_bib70","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41591-024-02813-1","article-title":"Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS\/pMMR colorectal cancer: a randomized phase 2 trial","volume":"30","author":"Wang","year":"2024","journal-title":"Nat. Med"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105353_bib71","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41416-023-02361-4","article-title":"Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities","volume":"129","author":"Wang","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105353_bib72","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13045-022-01294-4","article-title":"Exploring immunotherapy in colorectal cancer","volume":"15","author":"Weng","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105353_bib73","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41571-024-00943-6","article-title":"Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response","volume":"21","author":"Williams","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105353_bib74","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.celrep.2015.12.029","article-title":"Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis","volume":"14","author":"Xia","year":"2016","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105353_bib75","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13046-025-03377-9","article-title":"Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy","volume":"44","author":"Yang","year":"2025","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105353_bib76","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/s41417-024-00807-2","article-title":"The long-term effectiveness and mechanism of oncolytic virotherapy combined with anti-PD-L1 antibody in colorectal cancer patient","volume":"31","author":"Zhang","year":"2024","journal-title":"Cancer Gene Ther."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105353_bib77","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00262-025-04237-3","article-title":"Fruquintinib plus sintilimab in previously bevacizumab-treated, pMMR\/MSS refractory metastatic colorectal cancer: a phase 2 clinical trial","volume":"74","author":"Zhang","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105353_bib78","article-title":"Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:00:47Z","timestamp":1780038047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826002404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":78,"alternative-id":["S1040842826002404"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105353","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming conditional immune resistance in MSS and pMMR colorectal cancer: A sequential gating framework for immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105353","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105353"}}